Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation.

Airflow obstruction (AFO) Allogeneic hematopoietic stem cell transplantation Bronchiolitis obliterans syndrome Chronic graft-versus-host disease

Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
27 Aug 2024
Historique:
received: 06 12 2023
accepted: 05 08 2024
revised: 19 07 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 27 8 2024
Statut: aheadofprint

Résumé

Criteria for airflow obstruction (AFO) at one year after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pulmonary function tests (PFTs) are more stringent than the bronchiolitis obliterans syndrome (BOS) criteria of the National Institutes of Health. This single-center, retrospective cohort study evaluated the clinical impact of the AFO criteria at any time after transplantation. In 132 patients who underwent allo-HSCT from 2006 to 2016, the 2-year cumulative incidence of AFO was 35.0%, and the median time to diagnosis of AFO was 101 days after transplantation (range 35-716 days). Overall chronic graft-versus-host disease (cGVHD) incidence was significantly higher in patients with AFO than in those without AFO (80.4% vs. 47.7%, P < 0.01); notably, 37.0% of patients with AFO developed cGVHD after AFO diagnosis. AFO patients developed BOS with a 5-year cumulative incidence of 49.1% after AFO onset. The 5-year cumulative incidence of non-relapse mortality in the AFO group was higher than that in the non-AFO group (24.7% vs. 7.1%, P < 0.01). These results suggest that closely monitoring PFTs within two years after allo-HSCT, regardless of cGVHD status, is important for early detection of AFO and prevention of progression to BOS. (192words).

Identifiants

DOI: 10.1007/s12185-024-03831-y PMID: 39190255
pubmed: 39190255
doi: 10.1007/s12185-024-03831-y
pii: 10.1007/s12185-024-03831-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Bergeron A, Chevret S, Peffault De Latour R, Chagnon K, De Margerie-Mellon C, Rivière F, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018;51(5):1702617. https://doi.org/10.1183/13993003.02617-2017 .
doi: 10.1183/13993003.02617-2017 pubmed: 29650555
Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant. 2003;9(10):657–66. https://doi.org/10.1016/s1083-8791(03)00242-8 .
doi: 10.1016/s1083-8791(03)00242-8 pubmed: 14569562
Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–8. https://doi.org/10.1016/j.bbmt.2010.11.018 .
doi: 10.1016/j.bbmt.2010.11.018 pubmed: 21126596
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology. 2021;2021(1):578–86. https://doi.org/10.1182/hematology.2021000293 .
doi: 10.1182/hematology.2021000293 pubmed: 34889438 pmcid: 8791176
Astashchanka A, Ryan J, Lin E, Nokes B, Jamieson C, Kligerman S, et al. Pulmonary complications in hematopoietic stem cell transplant recipients—a clinician primer. J Clin Med. 2021;10(15):3227. https://doi.org/10.3390/jcm10153227 .
doi: 10.3390/jcm10153227 pubmed: 34362012 pmcid: 8348211
Shiari A, Nassar M, Soubani AO. Major pulmonary complications following Hematopoietic stem cell transplantation: what the pulmonologist needs to know. Respir Med. 2021;185: 106493. https://doi.org/10.1016/j.rmed.2021.106493 .
doi: 10.1016/j.rmed.2021.106493 pubmed: 34107323
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56. https://doi.org/10.1016/j.bbmt.2005.09.004 .
doi: 10.1016/j.bbmt.2005.09.004 pubmed: 16338616
Roca J, Grañeña A, Rodriguez-Roisin R, Alvarez P, Agusti-Vidal A, Rozman C. Fatal airway disease in an adult with chronic graft-versus-host disease. Thorax. 1982;37(1):77–8. https://doi.org/10.1136/thx.37.1.77 .
doi: 10.1136/thx.37.1.77 pubmed: 7071798 pmcid: 459252
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001 .
doi: 10.1016/j.bbmt.2014.12.001 pubmed: 25529383
Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone Marrow Transplant. 2013;48(6):819–24. https://doi.org/10.1038/bmt.2012.241 .
doi: 10.1038/bmt.2012.241 pubmed: 23208317
Jamani K, He Q, Liu Y, Davis C, Hubbard J, Schoch G, et al. Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):943–8. https://doi.org/10.1016/j.bbmt.2019.12.002 .
doi: 10.1016/j.bbmt.2019.12.002 pubmed: 31821885
Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant. 2015;21(6):1127–31. https://doi.org/10.1016/j.bbmt.2015.02.006 .
doi: 10.1016/j.bbmt.2015.02.006 pubmed: 25687798 pmcid: 4970454
Turner J, He Q, Baker K, Chung L, Lazarevic-Fogelquist A, Bethune D, et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transplant Cell Ther. 2021;27(7):616.e1-e66. https://doi.org/10.1016/j.jtct.2021.03.024 .
doi: 10.1016/j.jtct.2021.03.024
Cheng GS, Selwa KE, Hatt C, Ram S, Fortuna AB, Guerriero M, et al. Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Am J Transplant. 2020;20(8):2198–205. https://doi.org/10.1111/ajt.15814 .
doi: 10.1111/ajt.15814 pubmed: 32034974 pmcid: 7395854
Sharifi H, Lai YK, Guo H, Hoppenfeld M, Guenther ZD, Johnston L, et al. Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant. Chest. 2020;158(3):1090–103. https://doi.org/10.1016/j.chest.2020.02.076 .
doi: 10.1016/j.chest.2020.02.076 pubmed: 32343962 pmcid: 8097633
Walkup LL, Myers K, El-Bietar J, Nelson A, Willmering MM, Grimley M, et al. Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry. Eur Respir J. 2019;53(5):1801779. https://doi.org/10.1183/13993003.01779-2018 .
doi: 10.1183/13993003.01779-2018 pubmed: 30846475 pmcid: 6945824
Liu X, Yue Z, Yu J, Daguindau E, Kushekhar K, Zhang Q, et al. Proteomic characterization reveals that MMP-3 correlates with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell and lung transplantation. Am J Transplant. 2016;16(8):2342–51. https://doi.org/10.1111/ajt.13750 .
doi: 10.1111/ajt.13750 pubmed: 26887344 pmcid: 4956556
Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transplant. 2013;48(9):1224–9. https://doi.org/10.1038/bmt.2013.17 .
doi: 10.1038/bmt.2013.17 pubmed: 23435515
Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886–95. https://doi.org/10.1182/blood-2012-06-435008 .
doi: 10.1182/blood-2012-06-435008 pubmed: 23303823
Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168(2):208–14. https://doi.org/10.1164/rccm.200212-1468oc .
doi: 10.1164/rccm.200212-1468oc pubmed: 12649126
Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;33(7):759–64. https://doi.org/10.1038/sj.bmt.1704422 .
doi: 10.1038/sj.bmt.1704422 pubmed: 14968136
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244 pubmed: 24076552 pmcid: 3797171
Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report. Transplant Cell Ther. 2021;27(7):545–57. https://doi.org/10.1016/j.jtct.2021.03.033 .
doi: 10.1016/j.jtct.2021.03.033 pubmed: 33839317 pmcid: 8803210
Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129(4):448–55. https://doi.org/10.1182/blood-2016-08-693507 .
doi: 10.1182/blood-2016-08-693507 pubmed: 27856461 pmcid: 5270387
Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(9):547–53. https://doi.org/10.1038/sj.bmt.1705637 .
doi: 10.1038/sj.bmt.1705637 pubmed: 17351647
Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(1):63–7. https://doi.org/10.1038/sj.bmt.1705877 .
doi: 10.1038/sj.bmt.1705877 pubmed: 17934530
Williams KM, Cheng G-S, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–6. https://doi.org/10.1016/j.bbmt.2015.10.009 .
doi: 10.1016/j.bbmt.2015.10.009 pubmed: 26475726
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157–67. https://doi.org/10.1016/s2352-3026(19)30256-x .
doi: 10.1016/s2352-3026(19)30256-x pubmed: 32004485

Auteurs

Sanshiro Nakao (S)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.

Shokichi Tsukamoto (S)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.

Yusuke Takeda (Y)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.

Chikako Ohwada (C)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Hematology, International University of Health and Welfare, Narita, Japan.

Chihiro Ri (C)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Shintaro Izumi (S)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Yuri Kamata (Y)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Shinichiro Matsui (S)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Asuka Shibamiya (A)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Arata Ishii (A)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Koji Takaishi (K)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Kohei Takahashi (K)

Biostatistics Section, Clinical Research Centre, Chiba University Hospital, Chiba, Japan.

Yuki Shiko (Y)

Biostatistics Section, Clinical Research Centre, Chiba University Hospital, Chiba, Japan.

Nagisa Oshima-Hasegawa (N)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.

Tomoya Muto (T)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.

Naoya Mimura (N)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan.
Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.

Koutaro Yokote (K)

Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.

Chiaki Nakaseko (C)

Department of Hematology, International University of Health and Welfare, Narita, Japan.

Emiko Sakaida (E)

Department of Hematology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan. esakaida@faculty.chiba-u.jp.
Blood and Marrow Transplant Center, Chiba University Hospital, Chiba, Japan. esakaida@faculty.chiba-u.jp.
Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan. esakaida@faculty.chiba-u.jp.
Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan. esakaida@faculty.chiba-u.jp.
ORCID: 0000-0002-7254-1928

Classifications MeSH